<DOC>
	<DOCNO>NCT00080119</DOCNO>
	<brief_summary>Tuberculosis ( TB ) highly endemic sub-Saharan Africa . The increase burden TB setting high prevalence Human Immunodeficiency Virus ( HIV ) associate high rate transmission Mycobacterium tuberculosis ( M.tb ) adults child . Children infect TB high risk develop severe disease adult TB . The purpose study determine antibiotic isoniazid ( INH ) prevent TB infection infant bear HIV-infected mother .</brief_summary>
	<brief_title>Daily Isoniazid Prevent Tuberculosis Infants Born Mothers With HIV</brief_title>
	<detailed_description>Tuberculosis ( TB ) Human Immunodeficiency Virus ( HIV ) major public health problem southern Africa , incidence TB South Africa among high world . TB cause highly contagious bacterium Mycobacterium tuberculosis . The use Isoniazid ( INH ) prophylaxis adult associate reduced risk TB disease high-risk population . Delay initiate INH prophylaxis child result case childhood TB infection . This study evaluate effectiveness INH prophylaxis prevent TB infection infant bear HIV-infected mother southern Africa . Infants randomly assign receive either INH placebo mouth daily , begin 91st 120th day life , least 90 day Bacille Calmette-Guerin ( BCG ) vaccination . At site South Africa , HIV-infected infant receive daily trimethoprim/sulfamethoxazole ( TMP/SMX ) Pneumocystis jiroveci pneumonia ( PCP ) prophylaxis least 1 year age ; HIV-uninfected infant receive TMP/SMX least 6 month age . The study follow participant 192 week . Study visit occur study entry every 12 week week 192 . A physical exam blood collection occur study visit . Infants assess peripheral neuropathy every 12 week week 96 TB week 96 , 144 , 192 . The study also assess medication adherence . As November 12 , 2008 , follow-up revise . All participant permanently discontinue study follow-up February 28 , 2009 later May 31 , 2009 . Only clinical evaluation perform participant . For HIV-infected participant , study drug stop next scheduled visit . For HIV-uninfected subject , study drug discontinue immediately .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Mother HIVinfected . Hard copy documentation mother 's HIV infection unnecessary positive DNA PCR infant available . Received Bacille CalmetteGuerin ( BCG ) vaccine include 30th day life least 90 day prior study entry Able complete study requirement Physician assessment ageappropriate neurodevelopment chronological age correct gestational age prematurely born infant Parent legal guardian able willing provide sign informed consent Plan live study area least 4 year For inclusion HIVinfected stratum , infant must positive HIV1 DNA PCR ; inclusion HIVuninfected stratum , infant must negative HIV1 DNA PCR perform &gt; = 4 week age Previous diagnosis TB infection , TB disease current treatment TB infection TB disease Previous receipt INH Contact know acid fast bacillus ( AFB ) sputum smear culturepositive case TB study entry Current acute recurrent ( 3 prior episode ) low respiratory tract disease Chronic persistent diarrhea Failure thrive Contraindications use INH TMP/SMX Require certain medication Known suspect immune system diseases HIV Current previous diagnosis treatment cancer Current immunosuppressive therapy great 1 mg/kg/day prednisone equivalent Anticipated longterm oral intravenous corticosteroid therapy ( great 3 week ) . Those receive nonsteroidal antiinflammatory agent inhaled corticosteroid exclude . Grade 3 great AST/SGOT , ALT/SGPT , ANC , hemoglobin , platelet count , rash , neuropathy , myopathy screen Any Grade 4 clinical laboratory toxicity within 14 day prior study entry Other acute chronic condition , opinion investigator , may interfere study</criteria>
	<gender>All</gender>
	<minimum_age>91 Days</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>INH Prophylaxis</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>